The therapeutic community is excited with anticipation surrounding retatrutide, a new dual GIP and GLP-1 agonist that’s exhibiting significant promise in clinical trials for treating obesity. Unlike some current weight loss solutions, retatrutide appears to provide a significant substantial decrease in body mass and benefit metabolic health, part